Phase 3 Clinical Trials With Primary Completion Dates in October 2021
This is a list of Phase 3 trials with primary completion dates in October 2021 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| CBDY | Target Group Inc. | 2021-10-01 | Phase 3 | NCT04241315 | ELUCIDATE: Enabling Lung Cancer Identification Using Folate Receptor Targeting |
| CDTX | Cidara Therapeutics, Inc. | 2021-10-01 | Phase 3 | NCT03667690 | Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis |
| MIRM | Mirum Pharmaceuticals, Inc. | 2021-10-01 | Phase 3 | NCT03905330 | A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC) |
| NEPH | Nephros, Inc. | 2021-10-01 | Phase 3 | NCT04765371 | Comparison Between Prednisolone and Dexamethasone on Mortality in Patients on Oxygen Therapy, With CoViD-19 |
| RIGL | Rigel Pharmaceuticals, Inc. | 2021-10-01 | Phase 3 | NCT03764618 | A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA |
| STSA | Satsuma Pharmaceuticals, Inc. | 2021-10-01 | Phase 3 | NCT04406649 | A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine |
| SYGGF | Synairgen plc | 2021-10-01 | Phase 3 | NCT04732949 | Study to Assess Efficacy and Safety of Inhaled Interferon-β Therapy for COVID-19 |
| TNXP | Tonix Pharmaceuticals Holding Corp. | 2021-10-01 | Phase 3 | NCT04508621 | A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia |